Journal
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
Volume 43, Issue 1-2, Pages 71-80Publisher
KARGER
DOI: 10.1159/000454802
Keywords
Cerebrospinal fluid; Biomarkers; Sporadic Creutzfeldt-Jakob disease; Prion protein; Dementia
Categories
Funding
- European Commission [222887]
- EU [01ED1201A]
- Alzheimer-Forschungs-Initiative e.V. [AFI 12851]
- Federal Ministry of Education and Research grants within the German Network for Degenerative Dementia
Ask authors/readers for more resources
Background: Several biomarkers have been proposed to discriminate sporadic Creutzfeldt-Jakob disease (sCJD) from other dementias and control cases. However, their clinical accuracy depends on the PRNP codon 129 genotype, leaving it unclear how well established markers behave in untested conditions. Methods: We analyzed 14-3-3, tau, p-tau levels, and the p-tau/ tau ratio in a population sample collected from Polish hospitals including nondementia, dementia, and definite sCJD cases and validated their parameters according to previously established cutoffs. Additionally, the correlation between biomarkers and disease duration as well as the influence of the PRNP129 polymorphism are reported. Results: The tau levels and p-tau/tau ratios differed considerably between sCJD and clinically characterized non-CJD cases (p < 0.001). p-tau was only elevated in sCJD when compared to cases without dementia (p < 0.05). Tau and the p-tau/tau ratio showed a sensitivity of 95 and 100%, respectively, in detecting sCJD cases. A negative correlation between tau levels and disease duration, but not the timing of lumbar puncture was observed. Conclusion: The present findings confirmed the value of the p-tau/tau ratio as a robust sCJD biomarker and suggest a role for tau as prognostic marker. (C) 2017 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available